Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill,  invasively mechanically ventilated COVID-19 patients

Abstract Background Vilobelimab, a complement 5a (C5a)-specific monoclonal antibody, reduced mortality in critically ill COVID-19 patients in a phase 3 multicentre, randomized, double-blind, placebo-controlled study. As part of the study, vilobelimab concentrations and C5a levels as well as antidrug...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Endry H. T. Lim, Alexander P. J. Vlaar, Sanne de Bruin, Simon Rückinger, Claus Thielert, Maria Habel, Renfeng Guo, Bruce P. Burnett, James Dickinson, Matthijs C. Brouwer, Niels C. Riedemann, Diederik van de Beek, the PANAMO study group
Formato:	Artigo
Idioma:	Inglês
Publicado em:	SpringerOpen 2023-06-01
coleção:	Intensive Care Medicine Experimental
Assuntos:	PK Pharmacokinetic C5a Complement Vilobelimab ADA
Acesso em linha:	https://doi.org/10.1186/s40635-023-00520-8
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!